CATX vs. EMBC, IRMD, CBLL, BBNX, AVNS, BFLY, KIDS, RXST, BVS, and AXGN
Should you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Embecta (EMBC), Iradimed (IRMD), CeriBell (CBLL), Beta Bionics (BBNX), Avanos Medical (AVNS), Butterfly Network (BFLY), OrthoPediatrics (KIDS), RxSight (RXST), Bioventus (BVS), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.
Perspective Therapeutics vs.
Perspective Therapeutics (NYSE:CATX) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.
Perspective Therapeutics currently has a consensus price target of $12.50, indicating a potential upside of 398.01%. Embecta has a consensus price target of $20.33, indicating a potential upside of 93.47%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Perspective Therapeutics is more favorable than Embecta.
Embecta has a net margin of 5.25% compared to Perspective Therapeutics' net margin of -4,096.66%. Embecta's return on equity of -19.22% beat Perspective Therapeutics' return on equity.
Perspective Therapeutics received 33 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 97.22% of users gave Perspective Therapeutics an outperform vote while only 10.53% of users gave Embecta an outperform vote.
Perspective Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by insiders. Comparatively, 0.4% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Embecta has higher revenue and earnings than Perspective Therapeutics.
In the previous week, Perspective Therapeutics had 14 more articles in the media than Embecta. MarketBeat recorded 17 mentions for Perspective Therapeutics and 3 mentions for Embecta. Embecta's average media sentiment score of 1.03 beat Perspective Therapeutics' score of 0.90 indicating that Embecta is being referred to more favorably in the news media.
Summary
Perspective Therapeutics beats Embecta on 9 of the 17 factors compared between the two stocks.
Get Perspective Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Perspective Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:CATX) was last updated on 5/22/2025 by MarketBeat.com Staff